RxDoctor Payments Data

Peter Forman, PA

Physician Assistant · Brooklyn, NYNPI 1669084547

Payments from drug & device makers

$10,087in general payments, 2019–2025

Across 275 payments — averaging $36.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Axonics, Inc.$1K
  • Teleflex LLC$1K
  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$784
  • Johnson & Johnson$455
  • plus $3K from 20 others

What the payments were for

  • Consulting fees$2803%
  • Travel & lodging$1,96820%
  • Food & beverage$7,46274%
  • Education$3764%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,087 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$21,051
Medicare patients
76
Services billed
436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiaflexCollagenase Clostridium Hist.14$185,975
XtandiEnzalutamide14$181,318
Lupron DepotLeuprolide Acetate11$62,617
GemtesaVibegron78$56,118
MyrbetriqMirabegron35$22,067
Megestrol Acetate17$1,616
Tamsulosin Hcl88$1,251
Estradiol17$993
Bicalutamide24$680
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$444
Cephalexin44$410
Finasteride15$233
Alfuzosin Hcl ErAlfuzosin Hcl20$230
Ciprofloxacin Hcl57$207
Nystatin13$152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,021$203,38549 claims
Endo Pharmaceuticals Inc.Xiaflex$249$185,97514 claims
AbbVieLupron Depot$133$62,61711 claims
Sumitomo Pharma America, Inc.Gemtesa$784$56,11878 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →